Viracta Therapeutics, Inc. (VIRX)

NASDAQ: VIRX · IEX Real-Time Price · USD

0.514

-0.033 (-6.12%)

Jul 22, 2024, 10:04 AM EDT - Market open

Viracta Therapeutics Employees

Viracta Therapeutics had 40 employees as of December 31, 2023. The number of employees increased by 8 or 25.00% compared to the previous year.

Employees

40

Change (1Y)

8

Growth (1Y)

25.00%

Revenue / Employee

n/a

Profits / Employee

-$1,199,750

Market Cap

21.50M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	40	8	25.00%
Dec 31, 2022	32	8	33.33%
Dec 31, 2021	24	-	-

Related Stocks

Company Name	Employees
Cosmos Health	102
Cumberland Pharmaceuticals	91
Gain Therapeutics	32
AIM ImmunoTech	28
OneMedNet	20
Minerva Neurosciences	9
Aprea Therapeutics	7

Employee Rankings

VIRX News

2 months ago - Viracta Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
2 months ago - Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer - GlobeNewsWire
2 months ago - Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
2 months ago - Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
3 months ago - Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma - GlobeNewsWire
4 months ago - Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan - GlobeNewsWire
4 months ago - Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - GlobeNewsWire
5 months ago - Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial - GlobeNewsWire